ADUHELM attaches to and reduces amyloid plaques, a buildup of proteins in the brains of people with mild cognitive impairment (MCI) or mild dementia stage of Alzheimer’s disease.
Ask your doctor if ADUHELM is right for you.
Amyloid plaques are clumps of protein that may:
Your doctor will decide if you need further testing to check the levels of amyloid plaques in your brain.
ADUHELM is indicated for the treatment of Alzheimer’s disease. ADUHELM should be started in patients with mild cognitive impairment or mild dementia stage of disease, the population studied in clinical trials. There are no data on risks or benefits for patients in other stages of Alzheimer’s. ADUHELM is approved under accelerated approval based on reduction in amyloid plaques as seen in patients treated with ADUHELM. Continued approval of ADUHELM may require verification of clinical benefit in a confirmatory study.